- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- 13 Feb 20 424B4 Prospectus supplement with pricing info
- 13 Feb 20 EFFECT Notice of effectiveness
- 11 Feb 20 S-1/A IPO registration (amended)
-
3 Feb 20 S-1/A IPO registration (amended)
- 17 Jan 20 S-1 IPO registration
Exhibit 23.1
The reverse stock split described in Note 2 to the consolidated financial statements has not been consummated at February 3, 2020. When it has been consummated, we expect to be in a position to furnish the following consent.
/s/ PricewaterhouseCoopers LLP
San Jose, California
February 3, 2020
“CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the use in this Amendment No. 1 to the Registration Statement onForm S-1 of Revolution Medicines, Inc. of our report dated September 19, 2019, except for the effects of the reverse stock split described in Note 2, as to which the date is _______ relating to the financial statements of Revolution Medicines, Inc., which appears in this Registration Statement. We also consent to the reference to us under the heading “Experts” in such Registration Statement.
San Jose, California
_____________”